Immunosuppressants Market: By Drug Class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Others), By Indication (Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Immunosuppressants Market size was valued at USD 61.54 billion in 2022 and is expected to grow at a CAGR of 14.2% from 2023-2029. Immunosuppressants or anti-rejections are the medicinal substances, which prevent or inhibit the immune system activity. Immunosuppressants are most commonly used in the organ transplantation, autoimmune disorders such as Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and among others.  Moreover, immunosuppressants also used in some non-autoimmune inflammatory diseases such as ankylosing spondylitis. Immunodeficiency is the major adverse effect associated with the immunosuppressants as these drugs act non-selectively and increase the susceptibility to infections. In addition, dyslipidemia, peptic ulcers, hypertension, kidney injury, hyperglycemia, and hepatic injuries are other adverse effects with the immunosuppressants. Immunosuppressants market is growing at a significant CAGR owing to increase in the prevalence of autoimmune disorders and incidence of organ transplantation. For instance, According to World Health Organization, in 2014, approximately 119,873 organ transplantation cases were observed, which was increased about 1.8% from 2013. Furthermore, various pipeline products in the market also expected to bolster the market over the forecast period. Acquisitions & mergers, collaborations, and product launches are the strategies followed by the companies for increasing their revenue in immunosuppressants market.

Immunosuppressants Market Key Developments:

In September 2017, Zydus Cadila received FDA final approval for Mycophenolate Mofetil Immunosuppressant injection In April 2017, Sanofi received FDA approval for Thymoglobulin immunosuppressant drug used for the prevention of acute kidney transplant rejection.

Immunosuppressants Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Immunosuppressants Market Dynamics

Increase in the incidence of organ failure and there by rising demand for organ transplantation, technological advancements in organ transplantation procedures, and increase in the prevalence of autoimmune diseases are the factors anticipated to fuel the immunosuppressants market over the forecast period. Moreover, favourable reimbursement policies for immunosuppressants, development of newer therapeutic drugs, and various pipeline products might fuel the immunosuppressants market over the forecast period. However, stringent regulatory policies for drug approval, alternative therapies such as stem cell therapy for immunosuppression, and lack of awareness about immunosuppressants are the factors expected to hamper the growth of immunosuppressants market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Immunosuppressants Market Segmentation

By Drug Class
  • Corticosteroids
  • Monoclonal Antibodies (mAbs)
  • Calcineurin Inhibitors
  • mTOR Inhibitors
  • Anti-Proliferative Agents
  • Others
By Indication
  • Organ Transplantation
  • Autoimmune Disorders
  • Non-Autoimmune Inflammatory Diseases
By Route Administration
  • Oral
  • Parenteral
By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.



  • GlaxoSmithKline Plc. (U.K.)
  • Novartis AG (Switzerland)
  • Sanofi S.A. (France)
  • Pfizer, Inc. (U.S.)
  • Bristol Myers Squibb (U.S.)
  • F. Hoffmann La Roche Ltd. (Switzerland)
  • Astellas Pharma, Inc. (Japan)
  • Zydus Cadila (India)
  • Genzyme Corporation (U.S.)